Alpha-synuclein Antibodies

Type: drug

Status: Investigational

Developer: Roche (Prasinezumab)

Breakthrough Summary

No summary available.

Mechanism of Action

Antibodies targeting misfolded alpha-synuclein protein

Year: 2025